Abstract
Zn(ii)-based anticancer drugs can be suitable alternatives to conventional Pt(ii)-based drugs because of the unique chemical properties of Zn(ii) and low toxicity. In this study, a new hexadentate and heteroleptic Zn(ii) complex ([Zn(bpy)2(OAc)2], 1) was prepared with a conventional N,N-donor ligand (2,2'-bipyridine) and a leaving group (OAc) and characterized via ESI-MS, UV-Vis, and FT-IR spectroscopy. Kinetic and mechanistic investigations of 1 were performed using two biologically relevant ligands (dl-penicillamine and l-cysteine) to understand its selectivity and reactivity. Substitution reactions were determined to be two-step processes in the associative activation mode. Bioactivity studies of 1 revealed moderate to strong DNA-binding, cleaving ability, and antimicrobial properties.